Footnote:
†Including inhalations of selective β2-agonists, inhaled glucocorticoids, fixed combinations of β2-agonists and glucocorticoids, leukotriene receptor antagonists and xanthines.
‡Including chronic obstructive pulmonary disease, cystic fibrosis, sarcoidosis, primary adrenocortical insufficiency, pneumonitis due to external agents, inflammatory bowel disease, inflammatory polyarthropathies, systemic connective tissue disorders, inflammatory spondylopathies, and/or malignancy
Figure 2: Trends in the prevalence of oral corticosteroid use among young adults with asthma in Denmark from 1999-2018, given as annual prevalence stratified by A) OCS-exposure categories (low <5 mg OCS/day and high ≥5 mg OCS/day per year), B) by sex, and C) by age categories.